{"resourceType": "Citation", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"], "versionId": "21", "lastUpdated": "2025-10-13T09:55:39.733Z"}, "contained": [{"resourceType": "ArtifactAssessment", "id": "keywords0", "artifactReference": {"reference": "#", "type": "Citation"}, "content": [{"classifier": [{"text": "ADT"}]}, {"classifier": [{"text": "de novo metastatic"}]}, {"classifier": [{"text": "docetaxel"}]}, {"classifier": [{"text": "hormone-naive"}]}, {"classifier": [{"text": "prostate"}]}]}, {"resourceType": "Practitioner", "id": "contributor0", "name": [{"family": "Fizazi", "given": ["K"]}]}, {"resourceType": "Practitioner", "id": "contributor1", "name": [{"family": "Jenkins", "given": ["C"]}]}, {"resourceType": "Practitioner", "id": "contributor2", "name": [{"family": "Tannock", "given": ["I F"]}]}, {"resourceType": "ArtifactAssessment", "id": "meshHeading0", "artifactReference": {"reference": "#", "type": "Citation"}, "content": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000726", "display": "Androgen Antagonists", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000971", "display": "Antineoplastic Combined Chemotherapy Protocols", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D001859", "display": "Bone Neoplasms", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000188", "display": "drug therapy"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000556", "display": "secondary"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D018450", "display": "Disease Progression", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D018572", "display": "Disease-Free Survival", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000077143", "display": "Docetaxel", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D007987", "display": "Gonadotropin-Releasing Hormone", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000819", "display": "agonists"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D006801", "display": "Humans", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D008297", "display": "Male", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D009919", "display": "Orchiectomy", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is Major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D016016", "display": "Proportional Hazards Models", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D011471", "display": "Prostatic Neoplasms", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000188", "display": "drug therapy"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49488", "display": "Yes"}]}]}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000473", "display": "pathology"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D059039", "display": "Standard of Care", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D043823", "display": "Taxoids", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "Q000008", "display": "administration & dosage"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C49487", "display": "No"}]}]}]}]}]}], "useContext": [{"code": {"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "code": "fevir-platform-use", "display": "FEvIR Platform Use"}, "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "code": "medline-base", "display": "Medline Base", "userSelected": false}]}}], "classification": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "code": "citation-source", "display": "Citation Source"}]}, "classifier": [{"text": "MEDLINE"}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "code": "medline-owner", "display": "MEDLINE Citation Owner"}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value", "code": "NLM", "display": "National Library of Medicine, Index Section", "userSelected": false}]}]}], "statusDate": [{"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-received", "display": "PubMed Pubstatus of Received"}]}, "period": {"end": "2015-03-21"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-accepted", "display": "PubMed Pubstatus of Accepted"}]}, "period": {"end": "2015-05-13"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-entrez", "display": "PubMed Pubstatus of Entrez"}]}, "period": {"end": "2015-05-24T06:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-pubmed", "display": "PubMed Pubstatus of Pubmed"}]}, "period": {"end": "2015-05-24T06:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-medline", "display": "PubMed Pubstatus of Medline"}]}, "period": {"end": "2016-04-22T06:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-pmc-release", "display": "PubMed Pubstatus of PMC release"}]}, "period": {"end": "2016-08-01"}}], "citedArtifact": {"identifier": [{"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26002607"}, {"system": "https://www.ncbi.nlm.nih.gov/pmc/", "value": "PMC4511224"}, {"system": "https://doi.org", "value": "10.1093/annonc/mdv245"}, {"type": {"text": "pii", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "S0923-7534(19)31866-6"}], "title": [{"text": "Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.", "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}, "type": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/title-type", "code": "primary", "display": "Primary title"}]}]}], "abstract": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type", "code": "primary-human-use", "display": "Primary human use"}]}, "text": "Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (\u223c75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study.", "copyright": "\u00a9 The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com."}], "relatesTo": [{"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818\u2013823.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/24258693/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24258693", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079\u20131092.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/22424666/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "22424666", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/22529743/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "22529743", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348\u2013352.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/25311767/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25311767", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149\u2013158.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/23306100/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23306100", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362\u2013371.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/23163774/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23163774", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502\u20131512.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/15470213/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15470213", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242\u2013245.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/18182665/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "18182665", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513\u20131520.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/15470214/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15470214", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-na\u00efve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140."}, {"type": "cites", "citation": "Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198\u20131204.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/23910941/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23910941", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76\u201385.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/19198621/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "19198621", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "van Soest RJ, van Royen ME, de Morr\u00e9e ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821\u20133830.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/24200698/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24200698", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943\u20132947.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/22771826/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "22771826", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71\u2013e72.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/24837187/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24837187", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658\u2013667.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/22429837/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "22429837", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404\u2013e414.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/25079103/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25079103", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134\u20131141.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/10854947/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10854947", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825\u2013836.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/25097095/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25097095", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983\u2013985.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/23395593/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23395593", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (\u226570 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176\u20133183.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/23849828/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23849828", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904\u2013912.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/25218582/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25218582", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036\u20131042.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/9761805/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9761805", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419\u2013424.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/2503724/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "2503724", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314\u20131325.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/23550669/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23550669", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936\u20135942.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/19029421/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "19029421", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70\u2013E73.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/24589330/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24589330", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/25277272/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25277272", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the \u2018docetaxel era\u2019: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028\u20131038.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/25301760/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25301760", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229\u2013233.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/9000560/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9000560", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253\u2013265.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/15057285/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15057285", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60\u201367.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/17227493/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "17227493", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/16060722/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "16060722", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972\u20132977.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/24126362/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24126362", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953\u2013962.", "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/24424105/", "type": "Citation", "identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24424105", "assigner": {"display": "NLM"}}}}], "publicationForm": [{"publishedIn": {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/published-in-type", "code": "D020492", "display": "Periodical"}]}, "identifier": [{"type": {"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn", "code": "Electronic", "display": "Electronic"}], "text": "Electronic ISSN Type"}, "value": "1569-8041", "system": "https://portal.issn.org"}, {"type": {"text": "ISOAbbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.issn.org/services/online-services/access-to-the-ltwa/", "value": "Ann Oncol"}, {"type": {"text": "ISSN Linking", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/", "value": "0923-7534"}, {"type": {"text": "Medline Title Abbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html", "value": "Ann Oncol"}, {"type": {"text": "NLM Unique ID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local", "value": "9007735"}], "title": "Annals of oncology : official journal of the European Society for Medical Oncology", "publisherLocation": "England"}, "citedMedium": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-medium", "code": "internet", "display": "Internet"}]}, "volume": "26", "issue": "8", "articleDate": "2015-08", "pageString": "1660-7"}, {"citedMedium": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-medium", "code": "internet-without-issue", "display": "Internet without issue"}]}, "articleDate": "2015-05-22"}], "webLocation": [{"classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "code": "abstract", "display": "Abstract"}]}], "url": "https://pubmed.ncbi.nlm.nih.gov/26002607/"}, {"url": "https://doi.org/10.1093/annonc/mdv245", "classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "code": "doi-based", "display": "DOI Based"}]}]}], "classification": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "publishing-model", "display": "Publishing Model", "userSelected": false}]}, "classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "code": "Print-Electronic", "display": "Print Electronic", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "keyword", "display": "Keyword", "userSelected": false}]}, "artifactAssessment": [{"reference": "#keywords0", "type": "ArtifactAssessment", "display": "Keywords provided by NOTNLM"}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "chemical", "display": "Chemical", "userSelected": false}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D000726", "display": "Androgen Antagonists", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D043823", "display": "Taxoids", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "15H5577CQD", "userSelected": false}, {"system": "https://www.nlm.nih.gov/mesh", "code": "D000077143", "display": "Docetaxel", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "33515-09-2", "userSelected": false}, {"system": "https://www.nlm.nih.gov/mesh", "code": "D007987", "display": "Gonadotropin-Releasing Hormone", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}]}, "artifactAssessment": [{"reference": "#meshHeading0", "type": "ArtifactAssessment"}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "publication-type", "display": "Publication type"}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D016428", "display": "Journal Article", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D013485", "display": "Research Support, Non-U.S. Gov't", "userSelected": false}]}, {"coding": [{"system": "https://www.nlm.nih.gov/mesh", "code": "D016454", "display": "Review", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "knowledge-artifact-type", "display": "Knowledge Artifact Type", "userSelected": false}]}, "classifier": [{"coding": [{"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "code": "D016428", "display": "Journal Article", "userSelected": false}]}], "artifactAssessment": [{"display": "Classifier added by Computable Publishing LLC"}]}, {"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "code": "citation-subset", "display": "Citation subset", "userSelected": false}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset", "code": "IM", "display": "IM", "userSelected": false}]}]}], "contributorship": {"entry": [{"contributor": {"reference": "#contributor0", "type": "Practitioner", "display": "Fizazi K"}, "forenameInitials": "K", "affiliation": [{"display": "Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France."}]}, {"contributor": {"reference": "#contributor1", "type": "Practitioner", "display": "Jenkins C"}, "forenameInitials": "C", "affiliation": [{"display": "Med Ed, RMC, Exeter, UK."}]}, {"contributor": {"reference": "#contributor2", "type": "Practitioner", "display": "Tannock IF"}, "forenameInitials": "IF", "affiliation": [{"display": "Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca."}]}], "complete": true}}, "approvalDate": "2016-04-21", "lastReviewDate": "2024-05-16", "currentState": [{"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "medline-medline", "display": "Medline Citation Status of Medline"}]}, {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-publication-status-ppublish", "display": "PubMed PublicationStatus of ppublish"}]}], "title": "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net/FOI", "value": "179622", "assigner": {"display": "Computable Publishing LLC"}}, {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26002607"}], "status": "active", "url": "https://fevir.net/resources/Citation/179622", "id": "179622", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: MEDLINE-to-FEvIR Converter"}], "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code": "active", "display": "Active"}]}}], "description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."}